Ignite Creation Date:
2025-12-24 @ 5:52 PM
Ignite Modification Date:
2026-02-23 @ 1:11 AM
Study NCT ID:
NCT06592768
Status:
TERMINATED
Last Update Posted:
2025-09-16
First Post:
2024-09-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
Sponsor:
Jasper Therapeutics, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Allergic Asthma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Asthma | View |
| None | Allergy | View |
| None | Chronic Disease | View |
| None | Lung Function | View |
| None | Exacerbation | View |
| None | Bronchial Diseases | View |
| None | Respiratory Tract Diseases | View |
| None | Lung Diseases, Obstructive | View |
| None | Lung Diseases | View |
| None | Respiratory Hypersensitivity | View |
| None | Hypersensitivity, Immediate | View |
| None | Hypersensitivity | View |
| None | Immune System Diseases | View |